Buprenorphine treatment for people leaving jail
Part of Mental health clinical trials.
This trial offers buprenorphine (a medication for opioid use disorder) to people in jail who are soon to be released. It helps you start treatment while incarcerated and continue it after you return to the community, aiming to reduce overdose and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult in jail in the Baltimore area and expect to be released within 120 days
- You have a history of moderate or severe opioid use disorder (or were on buprenorphine or methadone in the year before jail)
- You are willing to start buprenorphine treatment (a shot or tablet) in jail and continue after release
- You do not have a serious untreated medical or mental health condition that would make buprenorphine risky
- You are not currently on methadone or naltrexone for opioid use in jail
- You do not have a known allergy to buprenorphine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This trial tests a way to quickly start buprenorphine (a medication for opioid addiction) in an outpatient clinic for people who use fentanyl. It aims to make starting treatment easier and faster, without needing to go through full withdrawal first.
This study tests whether a once-monthly injection of buprenorphine (called extended-release buprenorphine, or XR-B) works well for people in prison who are already in a medication program for opioid use disorder. It looks at preferences and outcomes in the last months before release.
This study tests whether switching from daily buprenorphine/naloxone (Suboxone) to a long-acting injectable buprenorphine (XRB) is safe and effective for men who are unsentenced and in jail for at least 4 days. It aims to see if the injection can help continue treatment without needing daily medication.
This study tests a behavioral support program designed to help people newly starting buprenorphine treatment for opioid use disorder stay engaged with their care. If you've recently started buprenorphine or just been released from incarceration and are beginning treatment, this trial may help you maintain consistent medication use and reduce the risk of relapse.
This trial tests a long-acting, once-monthly injection of buprenorphine (BRIXADI) given from a mobile pharmacy clinic. It aims to see if this approach is acceptable and practical for people with opioid use disorder, making treatment more accessible.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.